TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02362750

Intervention type: OTHER
Intervention: Organizational Interview
Description: Survivorship program leaders will participate in a phone-based organizational interview regarding the organization of the clinical survivorship care program.

Intervention type: OTHER
Intervention: Organizational Survey
Description: Survivorship program leaders will participate in a brief web-based organizational survey regarding the organization of the clinical survivorship care program.

Intervention type: OTHER
Intervention: Survivor Survey (1): Pre-Visit Baseline
Description: Survivors will participate in a baseline survey regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.

Intervention type: OTHER
Intervention: Survivor Survey (2): Post-Visit
Description: Survivors will participate in a survey within one week after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.

Intervention type: OTHER
Intervention: Survivor Survey (3): 3 Month Post-Visit
Description: Survivors will participate in a survey three months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.

Intervention type: OTHER
Intervention: Survivor Survey (4): 6 Month Post-Visit
Description: Survivors will participate in a survey six months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.

Intervention type: OTHER
Intervention: Clinician Survey
Description: Survivorship program clinicians will complete a survey for each survivor who enrolls in the study indicating services provided through the survivorship visit.
Study: NCT00972530

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: immobilisation in a triangular sling
Description: Intervention group: Immobilisation 48 hours in a triangular sling (mitella)~Control group: normal activity without restrictions
Study: NCT02124681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine sulfate 400mg/d PO for 13±1 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo PO for 13±1 weeks
Study: NCT04184622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT04056325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin
Description: Monotherapy, oral administration, single dose, fixed dose
Study: NCT03369249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Link2CARE
Description: The Link2CARE intervention consists of 4 sessions. Session 1 consists of a one-on-one meeting with a Health Coach, during which participants will be offered an oral rapid HIV test and STI test. Sessions 2, 3, and 4 are group-based. During these sessions, participants will engage in discussions and activities regarding sexual and substance use risk behaviors.
Study: NCT02735070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resfenol
Description: Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coristina d
Description: Patients included in the study will take the drugs 4 times a day, orally. Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
Study: NCT04056325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: Monotherapy, oral administration, single dose, weight dependent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Monotherapy, oral administration, single dose, matching number of tablets
Study: NCT02814942

Intervention type: DEVICE
Intervention: Cardiac Resynchronization Therapy
Description: Cardiac resynchronization therapy with or without ICD
Study: NCT04612257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin-alone closed-loop
Description: 40-hour intervention period using the insulin-alone closed-loop system.
Study: NCT00936000

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Protandim
Description: The dosage of Protandim will be 1350 mg per day given p.o. in two equally divided doses

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protandim
Description: The dosage of Protandim will be 1350 mg per day given p.o. in two equally divided doses
Study: NCT01837277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Description: Use of Dolutegravir -based regimens: patients will receive a Dolutegravir -based ART regimen (RAL 400 mg BID + TDF 300 mg QD + 3TC 150 mg BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz-based regimens
Description: Efavirenz-based regimens: patients will receive an EFV-based regimen (EFV 600 mg QD + TDGF 300 mg QD + 3TC 300 mg QD)
Study: NCT01621711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linkage patient activation intervention
Description: Usual Care plus Linkage encompassed Usual Care with the exception that the six 45-min Linkage patient activation education groups replaced the six 45-min Usual Care medical education groups, plus a linkage phone call (and/or a facilitated email) with the patient, clinician, and Primary Care physician.~The patient activation intervention components -- 1) six 45-min Linkage sessions on activation regarding overall health behaviors and 2) a linkage phone call (and/or a facilitated email) with the patient, clinician, and PC physician -- were delivered by a clinical psychologist.
Study: NCT00988988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AGEE cream
Description: AGEE cream is a creatine ethyl ester based product (an amino acid) that can be purchased over-the-counter without a prescription and is not FDA controlled. It will be used immediately after injection and repeated as needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Steroid Cream
Description: comparing to AGEE cream or placebo. 1% steroid cream is available over the counter. To be used immediately after injection and as needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical placebo cream with no active ingredients
Description: Cream to be applied immediately after injection and repeated as needed.
Study: NCT00622375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesalamine
Description: encapsulated mesalamine granules
Study: NCT03122210

Intervention type: DEVICE
Group type: OTHER
Intervention: Automated oxygen administration
Description: In the control group, usual oxygen administration and titration is planned

Intervention type: DEVICE
Group type: OTHER
Intervention: Automated oxygen administration
Description: In the control group, usual oxygen administration and titration is planned
Study: NCT02889354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Study: NCT01171716

Intervention type: OTHER
Group type: OTHER
Intervention: Meal Patterning
Description: LP intake 3 meals and 6 meals HP intake 3 meals and 6 meals
Study: NCT05039346

Intervention type: OTHER
Intervention: Phone interviews
Description: Phone interviews will be used to determine the patient's quality of life, symptoms and performance status

Intervention type: OTHER
Intervention: Phone interviews
Description: Phone interviews will be used to determine the patient's quality of life, symptoms and performance status
Study: NCT00337103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: 1.4 mg/m\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 2.5 g/m\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days
Study: NCT03122210

Intervention type: DEVICE
Group type: OTHER
Intervention: Automated oxygen administration
Description: In the control group, usual oxygen administration and titration is planned
Study: NCT05904574

Intervention type: OTHER
Intervention: Autologous blood patch
Description: Approximately 3-4 pieces were taken with the 18 G core biopsy needle until sufficient tissue was obtained. In the autologous blood patch technique, approximately 6-7 ml of blood was taken from the patient with a 10 ml syringe before the procedure. By attaching a 3-way tap to the injector from which the blood is drawn, blood is drawn into a second injector to ensure that the clotted blood is dispersed and homogenized. The prepared autologous blood patch was given through the coaxial needle (approximately 1 ml of autologous blood patch was applied for every 1 cm when the coaxial needle was withdrawn) and the tract formed by the biopsy needle in the parenchyma, pleura, and under the skin was closed with the patient's autologous blood.

Intervention type: OTHER
Intervention: Percutaneous transthoracic biopsy
Description: After determining the lung lobe where the lesion was observed, axial CT images of 5 mm cross-section thickness were obtained so that the upper and lower parts of it could be visualized. After ruling the entry site in the skin, antisepsis and local anesthesia were performed. The coaxial system (17 G) was cautiously advanced and CT images were continuously evaluated to confirm entrance into the lesion. Biopsy was taken and after sufficient tissue samples were taken at the last stage of the biopsy procedure, control CT imaging, including the whole lung, was performed to evaluate complications. The presences of pneumothorax were noted.

Intervention type: OTHER
Intervention: Percutaneous transthoracic biopsy
Description: After determining the lung lobe where the lesion was observed, axial CT images of 5 mm cross-section thickness were obtained so that the upper and lower parts of it could be visualized. After ruling the entry site in the skin, antisepsis and local anesthesia were performed. The coaxial system (17 G) was cautiously advanced and CT images were continuously evaluated to confirm entrance into the lesion. Biopsy was taken and after sufficient tissue samples were taken at the last stage of the biopsy procedure, control CT imaging, including the whole lung, was performed to evaluate complications. The presences of pneumothorax were noted.
Study: NCT00651716

Intervention type: OTHER
Intervention: flow cytometry
Description: Lymphocyte Analysis: Lymphocyte subset studies will be performed on samples obtained from the patient, donor, or graft. Aliquots will be analyzed using standard flow cytometry.

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Identification of gut-homing and skin-homing Treg subsets

Intervention type: OTHER
Intervention: Data Collection
Description: Patient samples will receive an alphanumeric code assigned by the principal investigator so that patient and donor identity will be known only to study investigators and research staff. Clinical records on each patient will be reviewed by participating investigators or research staff on a routine basis so that relevant clinical information including survival, malignancy relapse, and GVHD can be included in the patient database. Flow cytometry results will also be included in this database.
Study: NCT03423316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy
Description: The therapy will be conducted three times each week for 12 weeks. Each session takes 1 hour, consisting of 5 minutes of warmup activities, 50 minutes of intermittent exercise, and 5 minutes of cool-down activities. Exercise consists of walking on a treadmill initiated at 2 mph and 0% grade, until claudication pain becomes moderately severe. After claudication pain subsides, the subject will restart the walk. At the end of the session, the total exercise duration will be recorded. After a patient is able to walk 8-10 minutes at the initial workload, the grade is increased by 1-2%, or the speed is increased by 0.5 mph as tolerated.
Study: NCT00404352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RNF
Description: Single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months, or 36 months for patients enrolled in the OL extension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RNF
Description: Single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months, or 36 months for patients enrolled in the OL extension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RNF
Description: Single dose of RNF administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RNF
Description: Single dose of RNF administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 mL.
Study: NCT05145634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education related oral anticoagulants (OACs)
Description: The interventions administered to the experimental group were one-on-one instruction and Health Belief Model (HBM)-driven strategies, health information technology system, monthly telephone follow-ups, and providing medication cards. Patient education related oral anticoagulant: each subject in the experimental group was taught individually according to investigators' App in the outpatient department (OPD) by researchers. Every months, participants received a follow-up phone call to clarify any questions related to the knowledge of anticoagulants. The contents of the teaching material consisted of: the purpose of taking anticoagulant, side effects, adjustments to daily diet, and precautions (i.e.how to take medication safely, interaction between foods and medicine, prevention and checking of signs and symptoms of bleeding). The control group received the brochure and medical card after pretest and routine care in the OPD. All participants completed posttest at 3-month follow-up.
Study: NCT00823966

Intervention type: DRUG
Intervention: Rescriptor
Description: RESCRIPTOR® TABLETS 200mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dose is 400mg of Delavirdine Mesilate administered orally 3 times daily.This drug must always be administered in combination with other anti-HIV drugs.
Study: NCT02677688

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous EBV specific CTL infusion
Study: NCT04521244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrust joint lumbar manipulation
Description: Moist Hot pack of 14/15' over lumbar region for 15 mins. Hydro collator Temperature according to standardized hot pack is 40-45οC.Bilateral Thrust Manipulation of Lumbar Spine from L1-L5 Baseline Algometer for springing force tolerance and Lumbar Inclinometry using dual inclinometer for lumbar flexion, extension and goniometer for lumbar side bending.These pre and post intervention values were mentioned in questionnaire. The participants were administered with thrust and non-thrust manipulation of the lumbar spine and data was collected again immediately after the interventions without any delay.
Study: NCT02896673

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ventilatory conditions and measures with scanner and EIT
Description: Different ventilatory conditions are studied and measures are acquired with scanner and EIT~Time A: measure under basal conditions (TVbasal=6ml/kg of predicted weight), basal PEP, basal inspiratory time / total time = 30%)~Time B: different PEP are applied for 4 minutes: 5, 10, 15, 20 cm of H2O conserving the basal TV~Time C: different TV are applied for 4 minutes: 4, 7, 10 ml/kg of predicted weight conserving the basal PEP and the basal inspiratory time~Time D: recruitment in continuous positive airway pressure at 45 cm of H2O is performed for 30 seconds~Time E: return to adjustment period A
Study: NCT00473031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric restriction, high protein
Description: Weight loss with higher protein (35%) intake
Study: NCT04521244

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar mobilization
Description: Moist Hot pack of 14/15' from L1 where ribcage ends up to the region of gluteal folds for 15 mins. Non Thrust Manipulation for 30 seconds Using Kaltenborn grade 3 (Stretch rotation mobilization).Baseline Algometer for springing force tolerance and Lumbar Inclinometry using dual inclinometerfor lumbar flexion, extension and goniometer for lumbar side bending. These pre and post intervention values were mentioned in questionnaire. The participants were administered with thrust and non-thrust manipulation of the lumbar spine and data was collected again immediately after the interventions without any delay.
Study: NCT02694302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walkbot
Description: Walkbot(robot assisted gait training) 30 minutes and conventional physical therapy 30 minutes each per day to be administered 5 times a week for 3 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Conventional physical therapy 30 minutes to be administered twice a day, 5 times a week for 3 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: Conventional physical therapy 30 minutes to be administered twice a day, 5 times a week for 3 weeks.
Study: NCT00473031

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric restriction; normal protein
Description: Weight loss with recommended level of protein (18%)intake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Participants will be asked to attend eight 50-minute diet counseling sessions, with the opportunity to attend a total of approximately 28 diet counseling sessions, during the year.
Study: NCT02152176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titration of morphine by Patient Controlled Analgesy
Description: PCA is never used for titration but only for relay of titration. Self-controlled analgesia by PCA is our intervention.
Study: NCT05267119

Intervention type: PROCEDURE
Intervention: Swab
Description: The scalp was swabbed with five strokes which were performed each in a vertical, horizontal, left diagonal, and right diagonal direction. The swab was moved back and forth for 10 times
Study: NCT04291885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab IV infusion
Study: NCT01103427

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based behavioral coaching
Description: Those in the active comparator arm will benefit from automated coaching by e-mails with advice, information and support for smoking cessation. These e-mails will be adapted to their personal profile.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMS based coaching
Description: Those in the experimental SMS based coaching arm will benefit from automated coaching by SMS with advice, information and support for smoking cessation. These SMS's will be adapted to their personal profile.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMS coaching - UNN recruited
Description: Those in the experimental SMS based coaching arm- UNN recruited - will benefit from automated coaching by SMS with advice, information and support for smoking cessation. These SMS's will be adapted to their personal profile.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMS craving function - UNN recruited
Description: Those in the experimental SMS based craving/panic function arm - will in addition to the automated coaching by SMS have a panic/craving SMS function. Thus by sending a SMS they will receive instant advise and support for smoking cessation by SMS.
Study: NCT03236077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit and Fab
Description: participate in a targeted exercise program at the YMCA. Will include: Targeted exercise classes, Strength-training, Group support sessions
Study: NCT03936257

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Breastfeeding
Description: Infants were breastfed during 3 months minimum. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional BIO Infant formula
Description: Infant were fed during 6 months with a conventional BIO infant formula. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TrueGreen BIO infant formula
Description: Infant were fed during 6 months with the TrueGreen BIO infant formula. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis
Study: NCT02951494

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AlterG Anti-gravity treadmill
Description: Participants in this group will complete a 12 week aerobic exercise training protocol with 40% lower body weight support on an AlterG Anti-gravity treadmill
Study: NCT03093337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early post hospital discharge psychomotor therapy
Description: The intervention consisted on 20 psychomotor therapy sessions between 2 and 9 months, in order to support infants' development, and parent-infant interactions and adjustment. The therapy was based on body and emotional positive feelings and experiences, leading to improve sensory motor and perceptive integration, interactive and exploratory behaviors, physiological and tonic-emotional self-regulation, motor organization and early coordination. The intervention was a partnership with the parents, leading to decode the baby needs and expectations, for the parents to experiment more positive feelings, to become more confident in their own skills and more sensitive, and in synchrony with their baby. Intervention was supported by a detailed assessment scale implemented in the regional network related to the follow-up for vulnerable babies.